RxDoctor Payments Data

George Antonious, MD

Nephrology · Pensacola, FLNPI 1790761245

Payments from drug & device makers

$4,305in general payments, 2019–2025

Across 191 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$580
  • Amgen$486
  • Vifor Pharma, Inc.$425
  • Calliditas Therapeutics US Inc.$364
  • AstraZeneca$298
  • Aurinia Pharma U.S., Inc.$286
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,22798%
  • Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,305 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$555,411
Medicare patients
1,190
Services billed
3,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$256,767
FarxigaDapagliflozin Propanediol81$82,344
AuryxiaFerric Citrate13$47,083
EliquisApixaban37$35,242
Sevelamer Carbonate123$31,174
TrulicityDulaglutide28$29,628
LokelmaSodium Zirconium Cyclosilicate28$26,043
OzempicSemaglutide16$18,937
JardianceEmpagliflozin21$16,255
Calcium Acetate94$12,574
JanuviaSitagliptin Phosphate19$10,941
RestasisCyclosporine13$8,681
Calcitriol308$4,522
Cinacalcet Hcl26$4,306
Bumetanide51$3,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$580$256,76713 claims
AstraZenecaFarxiga, Lokelma$298$108,387109 claims
Akebia Therapeutics IncAuryxia$258$47,08313 claims
PfizerEliquis$15$35,24237 claims
Lilly USA, LLCTrulicity$131$29,62828 claims
Novo NordiskOzempic$24$18,93716 claims
MerckJanuvia$26$10,94119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →